Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences
- The
H.C. Wainwright 23rd AnnualGlobal Investment Conference taking placeSeptember 13-15, 2021 . Catalyst’s pre-recorded presentation will be available for viewing on-demand beginning Monday, September 13, 2021, at 7:00 AM EDT for those registered for the event. Catalyst’s management will host virtual 1x1 meetings throughout the day.
- 2021
Cantor Virtual Global Healthcare Conference taking placeSeptember 27 – 30, 2021. Catalyst’s management will present onSeptember 28th at 1:20 PM EDT and will host virtual 1x1 meetings throughout the day. The webcast will be available on the Company’s website and a replay will be accessible for at least 14 days.
The presentation will be available on the Investor section of the company's website promptly following the scheduled presentation times.
About
Firdapse® is currently being evaluated in clinical trials for the treatment of MuSK-MG and has received Orphan Drug Designation from the FDA for myasthenia gravis.
For additional information about the company, please visit www.catalystpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for fiscal year 2020 and its other filings with the
Source:
Investor Relations Contact:Mary Coleman Catalyst Pharmaceuticals (305) 420-3200 Mcoleman@catalystpharma.com Media Contact:David Schull Russo Partners (212) 845-4271 david.schull@russopartnersllc.com
Source: Catalyst Pharmaceuticals, Inc.